These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7094511)

  • 1. Hemodynamic effects of the antiarrhythmic drug pirmenol.
    Phillips HR; Stack RS; Davis DD; Morris KG; Lee KL; Shand DG; Pritchett EL
    Clin Pharmacol Ther; 1982 Aug; 32(2):235-9. PubMed ID: 7094511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute haemodynamic effects of the antiarrhythmic agent pirmenol in cardiac patients: a comparison with lidocaine.
    Nieminen MS; Toivonen LK; Manninen V; Frick MH
    Eur Heart J; 1986 Feb; 7(2):150-7. PubMed ID: 3516703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic effects of pirmenol and lidocaine: a placebo-controlled, double-blind, comparative study.
    Nieminen MS; Toivonen L; Manninen V; Frick H
    Am J Cardiol; 1987 Jun; 59(16):27H-32H. PubMed ID: 3296728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of intravenous pirmenol.
    Morris KG; Phillips HR
    Angiology; 1988 Mar; 39(3 Pt 2):321-6. PubMed ID: 3354931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of pirmenol, a new antiarrhythmic agent, assessed noninvasively.
    Toivonen LK; Nieminen MS
    Int J Cardiol; 1986 Feb; 10(2):111-8. PubMed ID: 3943931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology and pharmacokinetics of pirmenol.
    Reiter MJ
    Angiology; 1988 Mar; 39(3 Pt 2):293-8. PubMed ID: 3281518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease.
    Legrand V; Vandormael M; Collignon P; Kulbertus HE
    Am J Cardiol; 1983 Feb; 51(3):422-6. PubMed ID: 6823856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol.
    Reiter MJ; Hammill SC; Shand DG; Verghese C; McCarthy E; Pritchett EL
    Am J Cardiol; 1983 Jul; 52(1):83-7. PubMed ID: 6858934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of a new antiarrhythmic agent: cibenzoline.
    Rigaud M; Jouret G; Canal M; Bardet J; Flouvat B; Bourdarias JP
    J Pharmacol; 1985; 16(3):247-57. PubMed ID: 4068726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs.
    Janiczek N; Smith DE; Chang T; Ventura A; Mertz TE
    J Pharm Sci; 1997 Apr; 86(4):443-9. PubMed ID: 9109046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics.
    Hammill SC; Shand DG; Routledge PA; Hindman MC; Baker JT; Pritchett EL
    Circulation; 1982 Feb; 65(2):369-75. PubMed ID: 7053896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction.
    Lotto A; Finzi A; Massari FM; Pagnoni F; Valentini R; Ambrosini F; Lo Masto M
    G Ital Cardiol; 1984 Oct; 14(10):762-7. PubMed ID: 6519385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hemodynamic effects of intravenous tocainide in patients with heart disease.
    Winkle RA; Anderson JL; Peters F; Meffin PJ; Fowles RE; Harrison DC
    Circulation; 1978 Apr; 57(4):787-92. PubMed ID: 630689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirmenol hydrochloride (CI-845) and reference antiarrhythmic agents: effects on early ventricular arrhythmias after acute coronary artery ligation in anesthetized rats.
    Mertz TE; Kaplan HR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):580-6. PubMed ID: 7131307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacology of pirmenol.
    Kaplan HR; Mertz TE; Steffe TJ
    Am J Cardiol; 1987 Jun; 59(16):2H-9H. PubMed ID: 3591710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug.
    Garg DC; Jallad NS; Singh S; Ng KF; Weidler DJ
    J Clin Pharmacol; 1988 Sep; 28(9):812-7. PubMed ID: 2466056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirmenol: preclinical pharmacology.
    Kaplan HR; Mertz TE; Steffe TJ
    Angiology; 1988 Mar; 39(3 Pt 2):281-92. PubMed ID: 3281517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation.
    Jackson N; Verma SP; Frais MA; Silke B; Hafizullah M; Reynolds G; Taylor SH
    Clin Pharmacol Ther; 1985 Jun; 37(6):619-24. PubMed ID: 3891187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function].
    Drobinski G; Montalescot G; Moussallem N; Krumenacker M; Grosgogeat Y
    Therapie; 1990; 45(2):119-23. PubMed ID: 2191468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.